State of Alaska Department of Revenue Buys 920 Shares of ANI Pharmaceuticals, Inc. $ANIP

State of Alaska Department of Revenue increased its stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 10.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 10,116 shares of the specialty pharmaceutical company’s stock after buying an additional 920 shares during the quarter. State of Alaska Department of Revenue’s holdings in ANI Pharmaceuticals were worth $659,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of ANIP. Voya Investment Management LLC increased its holdings in ANI Pharmaceuticals by 12.0% during the 1st quarter. Voya Investment Management LLC now owns 8,934 shares of the specialty pharmaceutical company’s stock valued at $598,000 after purchasing an additional 957 shares in the last quarter. Jane Street Group LLC acquired a new stake in ANI Pharmaceuticals during the 1st quarter valued at $2,706,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in ANI Pharmaceuticals by 0.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 48,322 shares of the specialty pharmaceutical company’s stock valued at $3,235,000 after purchasing an additional 423 shares in the last quarter. Woodline Partners LP acquired a new stake in ANI Pharmaceuticals during the 1st quarter valued at $11,144,000. Finally, Parkman Healthcare Partners LLC acquired a new stake in ANI Pharmaceuticals during the 1st quarter valued at $7,030,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Stock Down 0.4%

NASDAQ:ANIP opened at $91.68 on Wednesday. ANI Pharmaceuticals, Inc. has a 12-month low of $52.50 and a 12-month high of $99.50. The company has a quick ratio of 1.96, a current ratio of 2.54 and a debt-to-equity ratio of 1.39. The firm has a market capitalization of $1.99 billion, a P/E ratio of -119.06 and a beta of 0.58. The stock’s fifty day simple moving average is $89.01 and its 200-day simple moving average is $73.55.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, August 8th. The specialty pharmaceutical company reported $1.80 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.42 by $0.38. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The business had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. During the same period last year, the company earned $1.02 EPS. The firm’s revenue was up 53.2% on a year-over-year basis. Equities research analysts expect that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ANIP shares. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, August 16th. HC Wainwright raised their price target on ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a report on Wednesday, September 17th. Piper Sandler reaffirmed an “overweight” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a report on Friday, August 8th. JPMorgan Chase & Co. raised their price target on ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, September 24th. Finally, Truist Financial increased their price objective on ANI Pharmaceuticals from $65.00 to $77.00 and gave the company a “hold” rating in a research report on Monday, August 11th. Two research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $97.29.

Insiders Place Their Bets

In other news, CEO Nikhil Lalwani sold 56,960 shares of the firm’s stock in a transaction on Tuesday, August 12th. The stock was sold at an average price of $85.93, for a total value of $4,894,572.80. Following the transaction, the chief executive officer directly owned 411,219 shares in the company, valued at $35,336,048.67. This trade represents a 12.17% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Muthusamy Shanmugam sold 52,990 shares of ANI Pharmaceuticals stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $87.15, for a total value of $4,618,078.50. Following the transaction, the chief operating officer owned 531,920 shares in the company, valued at approximately $46,356,828. This represents a 9.06% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 413,830 shares of company stock worth $36,495,294 over the last three months. Insiders own 12.70% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.